2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Treatment Considerations, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Diseases, Bleeding and Clotting, Thromboembolism, Thrombocytopenias, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, MPN, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant
PAPER

4851 Systemic low-dose tissue plasminogen activator for pediatric thrombosis: An 11-year single-center experience

Morgan Sumrall, CPNP-AC, Sydney Tharp, PA2, Clay Cohen, MD3, Sarah E Sartain, MD4
1 Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States
2 Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States
3 Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States
4 Baylor College of Medicine/Texas Children's Hospital, Houston, Texas, United States

Systemic tissue plasminogen activator (tPA) is often required in individuals with acute life-, limb-, or organ-threatening thrombosis. Data on systemic tPA use in children, however, remains limited, and current pediatric practice is largely extrapolated from adult studies. Systemic tPA is challenging in neonates due to the increased risk for intraventricular hemorrhage of prematurity, limiting its use.  

We performed a retrospective single-center review of patients ≤ 18 years of age who received systemic tPA at Texas Children’s Hospital between 2015 and 2026. Demographic, clinical, and treatment data were collected. Primary outcomes were thrombus resolution and bleeding (major, clinically relevant non-major [CRNMB], and minor, as defined by the International Society of Thrombosis and Haemostasis [ISTH]). Secondary outcomes included tPA dosing, infusion duration, and factors associated with thrombus resolution. Secondary analysis compared treatment characteristics and outcomes between children < 1 year and ≥ 1 year of age. The study was approved by the Baylor College of Medicine Institutional Review Board. Continuous variables were summarized as medians (interquartile ranges [IQR]) and compared using the Mann-Whtiney U test. Categorical variables were compared using Fisher’s exact test.  

Twenty patients underwent 22 thrombolytic treatment courses with systemic tPA over 11 years. Four treatment courses were temporarily interrupted and reinitiated, yielding a total of 26 individual tPA infusions. Median age at thrombolysis was 9 months (IQR 1.5 months – 7.4 years), including 4 neonates (3 full-term and 1 premature), 9 infants, and 9 children. Thrombosis location included arterial in 11 (50%), venous in 9 (41%), and intracardiac in 6 (27%) tPA courses; 3 patients had thrombi in more than one anatomical location. Complex congenital cardiac disease was present in 10 (50%). An identifiable provoking factor was present in 17 (85%), with central/arterial catheter attempt/placement and heart dysfunction being the most common. Two patients required repeat thrombolysis during separate hospitalizations secondary to recurrent thrombosis. Median infusion duration was 28 hours (IQR 14.7 – 42.1 hours). The median tPA starting dose was 0.08 mg/kg/hr (IQR 0.03-0.18) and the median maximum dose was 0.18 mg/kg/hr (IQR 0.06-0.29). Concurrent anticoagulation was administered during all treatment courses, with prophylactic-and therapeutic intensity anticoagulation used in 15 (68%) and 7 (32%) of courses, respectively. Fresh frozen plasma (FFP) was administered before or during thrombolysis in 11 (50%) treatment courses. Follow up imaging was available in 19 (86%), with partial or complete resolution occurring in 13 (68%) patients. Absolute D-dimer change, starting or maximum tPA dose, or FFP administration were not associated with thrombus resolution. Bleeding occurred during 8 (36%) of treatment courses, 4 (18%) with major, 2 (9%) with CRNMB, and 2 (9%) with minor bleeding episodes. Overall mortality was 45% (n=9). tPA contributed to 2 (10%) deaths in critically ill patients receiving salvage thrombolysis for massive thrombosis: a premature neonate with extensive intracardiac/IVC thrombus (pulmonary hemorrhage) and a patient with cystic fibrosis and SVC syndrome (intracranial hemorrhage). Among children < 1 year, compared to older children, any type of bleeding occurred in 3 (23%) vs. 5 (56%), respectively, (p=0.19), but thrombus resolution only occurred in 6/11 (55%) vs. 7/8 (88%), respectively, (P=0.18) despite higher median starting tPA doses (infant: 0.10 mg/kg/hr vs. child: 0.05 mg/kg/hr) and maximum tPA doses (infant: 0.20 mg/kg/hr vs. child: 0.07 mg/kg/hr).   

In conclusion, our single-center review demonstrated that in children with high-risk thromboses, systemic tPA resulted in reduction in thrombus burden in about 70%, though carried a significant bleeding risk, with nearly 30% having clinically relevant bleeding complications. Despite receiving numerically higher tPA doses, children younger than 1 year of age experienced less bleeding compared with older children, supporting the consideration of carefully monitored systemic thrombolysis in this population. Further prospective studies are needed to determine whether lower thrombus resolution observed in younger children reflects age-related differences in thrombus biology, treatment timing, or optimal dosing. 

Morgan Sumrall, CPNP-AC: No relevant conflicts of interest to declare.